Aligos Therapeutics, Inc.

NasdaqCM:ALGS Stok Raporu

Piyasa değeri: US$74.4m

Aligos Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

Aligos Therapeutics CEO'su Larry Blatt, Feb2018 tarihinde atandı, in görev süresi 6.75 yıldır. in toplam yıllık tazminatı $ 1.34M olup, şirket hissesi ve opsiyonları dahil olmak üzere 43.7% maaş ve 56.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.32% ine doğrudan sahiptir ve bu hisseler $ 1.72M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 3.6 yıldır.

Anahtar bilgiler

Larry Blatt

İcra Kurulu Başkanı

US$1.3m

Toplam tazminat

CEO maaş yüzdesi43.7%
CEO görev süresi6.8yrs
CEO sahipliği2.3%
Yönetim ortalama görev süresi5.3yrs
Yönetim Kurulu ortalama görev süresi3.6yrs

Son yönetim güncellemeleri

Recent updates

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Jul 31
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Jul 16
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

May 24
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24
Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01
We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16
What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

CEO Tazminat Analizi

Larry Blatt'un ücretlendirmesi Aligos Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$77m

Jun 30 2024n/an/a

-US$76m

Mar 31 2024n/an/a

-US$100m

Dec 31 2023US$1mUS$587k

-US$88m

Sep 30 2023n/an/a

-US$82m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$83m

Dec 31 2022US$2mUS$549k

-US$96m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$126m

Mar 31 2022n/an/a

-US$136m

Dec 31 2021US$873kUS$549k

-US$128m

Sep 30 2021n/an/a

-US$125m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$116m

Dec 31 2020US$7mUS$493k

-US$109m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$62m

Dec 31 2019US$674kUS$475k

-US$52m

Tazminat ve Piyasa: Larry 'nin toplam tazminatı ($USD 1.34M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 649.07K ).

Tazminat ve Kazançlar: Larry 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Larry Blatt (62 yo)

6.8yrs

Görev süresi

US$1,344,458

Tazminat

Dr. Lawrence M. Blatt, also known as Larry, Ph D., MBA, has been Chief Executive Officer and Director at Aligos Therapeutics, Inc. since February 2018 and also has been its Chairman of the Board since June...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Lawrence Blatt
CEO, President & Chairman of the Board6.8yrsUS$1.34m2.32%
$ 1.7m
Julian Symons
Executive VP & Chief Scientific Officer6.5yrsUS$836.32k0.42%
$ 315.9k
Lesley Calhoun
Executive VP & CFO4.4yrsVeri yokVeri yok
Kristina Engeseth
VP and Head of People & Culture2.8yrsVeri yokVeri yok
Sushmita Chanda
Executive Vice President & Chief Development Officer6.3yrsVeri yokVeri yok
David Smith
Executive VP & Head of Chemical Operations6.3yrsVeri yokVeri yok
Tse-I Lin
VP of Early Compound Development & Belgian Site Head2.8yrsVeri yokVeri yok
Hardean Achneck
Chief Medical Officerless than a yearVeri yokVeri yok

5.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim: ALGS 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Lawrence Blatt
CEO, President & Chairman of the Board6.8yrsUS$1.34m2.32%
$ 1.7m
Carole Nuechterlein
Independent Director6.3yrsUS$12.90kVeri yok
K. Hirth
Independent Director6.3yrsUS$60.40k0.064%
$ 47.7k
James Scopa
Independent Director3.6yrsUS$67.90k0.20%
$ 146.8k
Heather Preston
Independent Directorless than a yearVeri yokVeri yok
Margarita Chavez
Independent Directorless than a yearVeri yokVeri yok
Bridget Martell
Independent Director3yrsUS$52.90kVeri yok

3.6yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALGS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).